Mesenchymal Stem Cell in Mice Uterine and Its Therapeutic Effect on Osteoporosis

Wang, Zhe; Deng-gao, Wang; Liu, Yakun; Liu, Dan; Ren, Yixiong; Liu, Zhizhen; Yu, Bin; Hao, Min; Xie, Jun

doi:10.1089/rej.2019.2262

Cited by 7 publications

(4 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Stem cells play an important role in the development of OP. Wang et al found that in the osteoporosis model, stem cells with osteogenic differentiation potential could stably differentiate and improve the reduction in bone density [38]. MSC transplantation in OP treatment raised osteogenic differentiation and halt the deterioration of OP [39].…”

Section: Discussionmentioning

confidence: 99%

Loss of N-acetylglucosaminyl transferase V is involved in the impaired osteogenic differentiation of bone marrow mesenchymal stem cells

Liu

et al. 2023

Exp. Anim.

View full text Add to dashboard Cite

The imbalance of bone resorption and bone formation causes osteoporosis (OP), a common skeletal disorder. Decreased osteogenic activity was found in the bone marrow cultures from MGAT5-deficient mice. We hypothesized that MGAT5 was associated with osteogenic differentiation of bone marrow mesenchymal stem cells (BMSCs) and involved in the pathological mechanisms of osteoporosis. To test this hypothesis, the mRNA and protein expression levels of MGAT5 were determined in bone tissues of ovariectomized (OVX) mice, a well-established OP model, and the role of MGAT5 in osteogenic activity was investigated in murine BMSCs. As expected, being accompanied by the loss of bone mass density and osteogenic markers (runt-related transcription factor 2, osteocalcin and osterix), a reduced expression of MGAT5 in vertebrae and femur tissues were found in OP mice. In vitro, knockdown of MGAT5 inhibited the osteogenic differentiation potential of BMSCs, as evidenced by the decreased expressions of osteogenic markers and less alkaline phosphatase and alizarin red S staining. Mechanically, knockdown of MGAT5 suppressed the nuclear translocation of β-catenin, thereby downregulating the expressions of downstream genes c-myc and axis inhibition protein 2, which were also associated with osteogenic differentiation. In addition, MGAT5 knockdown inhibited bone morphogenetic protein/transforming growth factor (TGF)-β signaling pathway. In conclusion, MGAT5 may modulate the osteogenic differentiation of BMSCs via the β-catenin, BMP2 and TGF-β signals and involved in the process of OP.

show abstract

Section: Discussionmentioning

confidence: 99%

Loss of N-acetylglucosaminyl transferase V is involved in the impaired osteogenic differentiation of bone marrow mesenchymal stem cells

Liu

et al. 2023

Exp. Anim.

View full text Add to dashboard Cite

show abstract

“…Additionally, numerous clinical studies have been conducted on Duchene muscular dystrophy, heart failure, and multiple sclerosis (19,20). The results of these studies are promising for the future of stem cell therapy (21)(22)(23).…”

Section: Introductionmentioning

confidence: 99%

Human Endometrial Regenerative Cells for Neurological Disorders: Hype or Hope?

Momeni,

Naserzadeh,

Sepehrinezhad

et al. 2024

Int J Stem Cells

View full text Add to dashboard Cite

Despite enormous efforts, no effective medication has been found to significantly halt or even slow the progression of neurological diseases, such as acquired (e.g., traumatic brain injury, spinal cord injury, etc.) and chronic (e.g., Parkinson's disease, Alzheimer's disease, etc.) central nervous system disorders. So, researchers are looking for alternative therapeutic modalities to manage the disease's symptoms and stop it from worsening. Concerning disease-modifying capabilities, stem cell therapy has emerged as an expanding domain. Among different types of stem cells, human endometrial regenerative cells have excellent regenerative properties, making them suitable for regenerative medicine. They have the potential for self-renewal and differentiation into three types of stem cells: epithelial stem cells, endothelial side population stem cells, and mesenchymal stem cells (MSCs). ERCs can be isolated from endometrial biopsy and menstrual blood samples. However, there is no comprehensive evidence on the effects of ERCs on neurological disorders. Hence, we initially explore the traits of these specific stem cells in this analysis, followed by an emphasis on their therapeutic potential in treating neurological disorders.

show abstract

“…Osteoporosis is one of the major epidemics of the twenty-first century, affecting about 200 million people around the world [ 1 ], which seriously endangers people's health. As a dynamic organ, bone mass maintenance depends on the balance between osteoblast-mediated bone formation and osteoclast-mediated bone resorption [ 2 ]. The imbalance between the activity of osteoblasts and osteoclasts will lead to increased bone fragility and increased incidence of fractures [ 3 ].…”

Section: Introductionmentioning

confidence: 99%

Oridonin Attenuates Thioacetamide-Induced Osteoclastogenesis Through MAPK/NF-κB Pathway and Thioacetamide-Inhibited Osteoblastogenesis Through BMP-2/RUNX2 Pathway

Jin

Yang

et al. 2023

Calcif Tissue Int

View full text Add to dashboard Cite

Osteoporosis, an age-related metabolic bone disease, is mainly caused by an imbalance between osteoblast-mediated bone formation and osteoclast-mediated bone resorption. At present, there are many osteoporosis drugs that can promote bone formation or inhibit bone resorption. However, there were few therapeutic drugs that can simultaneously promote bone formation and inhibit bone resorption. Oridonin (ORI), a tetracyclic diterpenoid compound isolated from Rabdosia rubescens, has been proved to have anti-inflammatory, anti-tumor effects. However, little is known about the osteoprotective effect of oridonin. Thioacetamide (TAA) is a common organic compound with significant hepatotoxicity. Recent studies have found that there was a certain association between TAA and bone injury. In this work, we investigated the effect and mechanism of ORI on TAA-induced osteoclastogenesis and inhibition of osteoblast differentiation. The results showed that TAA could promote the osteoclastogenesis of RAW264.7 by promoting the MAPK/NF-κB pathway, and also promoted p65 nuclear translocation and activated intracellular ROS generation, and ORI can inhibit these effects to inhibit TAA-induced osteoclastogenesis. Moreover, ORI can also promote the osteogenic differentiation pathway and inhibit adipogenic differentiation of BMSCs to promote bone formation. In conclusion, our results revealed that ORI, as a potential therapeutic drug for osteoporosis, could protect against TAA-induced bone loss and TAA-inhibited bone formation.

show abstract

Mesenchymal Stem Cell in Mice Uterine and Its Therapeutic Effect on Osteoporosis

Cited by 7 publications

References 43 publications

Loss of N-acetylglucosaminyl transferase V is involved in the impaired osteogenic differentiation of bone marrow mesenchymal stem cells

Loss of N-acetylglucosaminyl transferase V is involved in the impaired osteogenic differentiation of bone marrow mesenchymal stem cells

Human Endometrial Regenerative Cells for Neurological Disorders: Hype or Hope?

Oridonin Attenuates Thioacetamide-Induced Osteoclastogenesis Through MAPK/NF-κB Pathway and Thioacetamide-Inhibited Osteoblastogenesis Through BMP-2/RUNX2 Pathway

Contact Info

Product

Resources

About